Pharmaceuticals Middle East

Middle East Oncology Biosimilars Market Analysis, 2024–2034

Updated Reviewed by Chandani Patel

Middle East Oncology Biosimilars Market Industry Trends and Forecast to 2034: Segmented by (Molecule, Cancer, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Middle East · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $405.4 Mn Placeholder estimate
Estimate 2025 $471.5 Mn 4% of the global market
Projected 2034 $1.84 Bn 289.2% Adds $1.36 Bn over 9 forecast years
CAGR 2025–2034 16.3% Faster than 77% of 180 Pharmaceuticals markets here
Key players 6 +1
  • Middle East is 3.96% of the global market.
  • Among regions, the largest is North America at $6.50 Bn.
  • Fastest growing: Africa at 16.4% a year.
  • Middle East ranks 5th of 6 by size among regions.

Market size projection

Middle East

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$1.36 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Oncology Biosimilars Market market size by year, Middle East
YearMarket sizeChange that yearSince 2025
2024 (estimate) $405.4 Mn — —
2025 (base) $471.5 Mn +$66.1 Mn —
2026 (forecast) $548.4 Mn +$76.9 Mn +16.3%
2027 (forecast) $637.7 Mn +$89.4 Mn +35.3%
2028 (forecast) $741.7 Mn +$104.0 Mn +57.3%
2029 (forecast) $862.6 Mn +$120.9 Mn +82.9%
2030 (forecast) $1.00 Bn +$140.6 Mn +112.8%
2031 (forecast) $1.17 Bn +$163.5 Mn +147.4%
2032 (forecast) $1.36 Bn +$190.2 Mn +187.8%
2033 (forecast) $1.58 Bn +$221.2 Mn +234.7%
2034 (forecast) $1.84 Bn +$257.2 Mn +289.2%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $11.90 Bn
  2. North America $6.50 Bn
  3. US $4.41 Bn
  4. Europe $2.39 Bn
  5. APAC $2.20 Bn
  6. China $927.5 Mn
  7. Canada $887.7 Mn
  8. Japan $636.5 Mn
  9. Latin America $578.1 Mn
  10. Germany $452.7 Mn
  11. Middle East (this report) $471.5 Mn
  12. France $371.6 Mn
  13. Brazil $336.0 Mn
  14. Italy $302.5 Mn
  15. UK $282.2 Mn
  16. Ecuador $236.9 Mn
  17. Spain $202.5 Mn
  18. India $212.2 Mn
  19. Saudi Arabia $205.4 Mn
  20. Mexico $160.2 Mn
  21. Africa $157.7 Mn
  22. Australia $148.3 Mn
  23. New Zealand $138.8 Mn
  24. Russia $110.4 Mn
  25. South Africa $79.0 Mn
  26. UAE $51.8 Mn
  27. Egypt $35.2 Mn
  28. Philippines $22.8 Mn
  29. Hong Kong $22.1 Mn
  30. Malaysia $18.0 Mn
  31. Thailand $16.5 Mn
  32. Singapore $12.8 Mn
  33. Kenya $7.4 Mn

Report snapshot

Middle East Oncology Biosimilars Market Analysis at a glance
Market size, 2025$471.5 Mn placeholder estimate
Forecast, 2034$1.84 Bn placeholder estimate
Growth (CAGR), 2025–203416.3% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsMolecule, cancer and end user (see all)
Key playersAmgen Inc., Sandoz, Pfizer Inc., Celltrion, Samsung Bioepis and 1 more (see all)
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Middle East Oncology Biosimilars Market Analysis Executive Summary

Oncology biosimilars are lower-cost versions of cancer biologic drugs such as trastuzumab and bevacizumab.

Key segments of the oncology Biosimilars market include molecule (Trastuzumab, Bevacizumab and Rituximab) and cancer (Breast, Colorectal and Lymphoma).

Bar chart: Middle East Oncology Biosimilars market size, 2024–2034, placeholder estimates. $405.4 Mn in 2024, $471.5 Mn in 2025 and $1.84 Bn in 2034, 16.3% CAGR.
Middle East Oncology Biosimilars market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Middle East Oncology Biosimilars Market Dynamics

Market Growth Drivers

Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the oncology Biosimilars market. Faster approvals and new combinations are improving survival.

Opportunity

Biomarker-led treatment, earlier lines of therapy and expansion into emerging markets offer strong growth for the oncology Biosimilars market.

Market Restraints

High treatment costs, drug resistance, side effects and unequal access to cancer centres hold back the oncology Biosimilars market, especially in low- and middle-income countries.

Competitive Landscape for Oncology Biosimilars Market in Middle East

The oncology Biosimilars market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Oncology Biosimilars Market in Middle East

Oncology Biosimilars in Middle East: rules and payment

In some of the countries we cover here, medicines are approved by SFDA (Saudi Arabia)⁠[1] and EDE (UAE)⁠[2]. How care is paid for in some of these countries: free public care and CHI-regulated insurance (Saudi Arabia)⁠[3] and mandatory health insurance (UAE)⁠[4].

[1] Saudi Food and Drug Authority. Checked 14 Nov 2026.

[2] Emirates Drug Establishment. Checked 14 Nov 2026.

[3] Council of Health Insurance. Checked 14 Nov 2026.

[4] Ministry of Human Resources and Emiratisation. Checked 14 Nov 2026.

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for oncology Biosimilars. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Middle East.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Oncology Biosimilars right now, from free public sources.

Latest research 23 papers since 2021 (worldwide)

  1. Adoption of Bevacizumab Biosimilars in Medicare Part B: Socioeconomic and Geographic Variation, 2019-2023. JCO oncology practice, 2026
  2. Pricing for Oncology Biosimilars. JAMA, 2026
  3. Pricing for Oncology Biosimilars-Reply. JAMA, 2026
  4. Hospital Adoption and Pricing for Oncology Biosimilars. JAMA, 2026
  5. Real-World Evidence Assessing the Safety of Administering Intravenous Rituximab Biosimilar in the First Cycle and Subcutaneous Rituximab in Subsequent Cycles in B-Cell Lymphoma Patients. Pharmacy (Basel, Switzerland), 2025
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Oncology Biosimilars in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Oncology Biosimilars market in Middle East?
Placeholder estimate: about $471.5 Mn in 2025, rising to about $1.84 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Oncology Biosimilars market in Middle East growing?
Placeholder estimate: about 16.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Oncology Biosimilars market report cover?
The report splits the market by molecule (Trastuzumab, Bevacizumab, Rituximab, Pegfilgrastim and more), cancer (Breast, Colorectal, Lymphoma, Supportive Care) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Oncology Biosimilars market?
Key players include Amgen Inc., Sandoz, Pfizer Inc., Celltrion, Samsung Bioepis and Biocon.
What is driving the Oncology Biosimilars market?
Rising cancer cases, earlier detection, precision medicine and a strong pipeline of targeted and immune therapies are driving the oncology Biosimilars market. Faster approvals and new combinations are improving survival.
How much research is published on Oncology Biosimilars?
PubMed lists 23 papers on Oncology Biosimilars added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Oncology Biosimilars in Middle East? Our analysts can size it for your plan. Talk to us See the public data Early deaths from long-term diseases (WHO) for every country, free. Open the Public Health Dashboard

From our blog

Brain Cancer Diagnosis: Imaging and New BiomarkersAbout 321,000 people were diagnosed with brain and nervous system tumours in 2022, and about 248,000 died… Bioinformatics: Making Sense of Health DataSequencing a human genome fell from about $50 million in 2003 to under $1,500 by late 2015. Bioinformatics… Dermatology Diagnostics: AI and Skin HealthSkin cancers caused over 1.5 million new cases in 2022. Imaging and AI tools are changing how skin conditions…
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in Middle East

See all
Same topic, other categories

Related on oncology and biologics and biosimilars

See the topic